|
2.5 Etiologie - Gènes
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
4.7 Dép., diag. & prono. - Col de l'utérus
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5.10 Traitements - Essais
|
|
|
Good progress in clinical trials transparency, but we need to do more [Cancer Research UK]
|
|
|
|
|
|
These
highlights of cancer clinical trial practice in the UK show that
transparency is possible. Now we need this good practice – clinical
trial registration and open reporting of trial results – to be
replicated in other disease areas, not just in the UK but around the
world, and retrospectively for all the hidden trials of medicines we use
today that were conducted in the past.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
|
6.1 Observation
|
|
|
|
6.10 Politiques
|
|
|
Vice President Highlights CancerLinQ™ at World Economic Forum [ASCO]
|
|
|
|
|
|
Biden
presided over a panel discussion with leading healthcare policy, cancer
research, and technology experts that explored the importance of
sharing data and improving interoperability of patient information in
cancer care, among other issues in cancer research and treatment. Watch
the full video which mentions CancerLinQ at the 9:40 mark.
|
|
|
|
|
|
|
6.7.3 DMP
|
|
|